Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes mellitus impacts nearly 7% of the global population, contributing to cardiovascular disease and heart failure.
• Traditional cardiovascular disease pharmacotherapies focus on blood pressure, insulin, cholesterol, renin-angiotensin system inhibition, and catecholamine blockade.
• Emerging evidence highlights the cardiovascular protective benefits of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in diabetic and non-diabetic individuals.

Purpose of the Study:

• To review the impact of SGLT-2 inhibitors on serum biomarkers of cardiac function.
• To elucidate how these biomarkers reflect physiological changes in cardiovascular function due to SGLT-2 inhibitor use.

Main Methods:

• Narrative review of existing literature.
• Analysis of studies reporting biomarker changes associated with SGLT-2 inhibitor therapy.
• Synthesis of findings on biomarker alterations and their physiological implications.

Main Results:

• SGLT-2 inhibitors are associated with significant alterations in serum biomarkers indicative of cardiac function.
• These biomarker changes reflect underlying physiological adaptations in cardiovascular health.
• The protective effects extend to patients with and without diabetes.

Conclusions:

• SGLT-2 inhibitors represent a significant advancement in cardiovascular disease management.
• Monitoring cardiac biomarkers can provide insights into the cardioprotective mechanisms of SGLT-2 inhibitors.
• Further research is warranted to fully understand the long-term implications of these biomarker shifts.